Strensiq 40 (Asfotase Alfa Vials) 40mg/ml -40mg INJ 1ml

Strensiq 40 (asfotase alfa) is an injectable enzyme replacement therapy used to treat metabolic bone disease. Store between 2-8°C and protect from light. Seek medical advice for proper handling and administration.

Strength

40mg/ml -40mg INJ 1ml

Pack Size

12s

Storage

2-8°

Manufacturer / TM Owner

Alexion

Select Quantity

Pack/s

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

First Name

Last Name

Phone

Delivery Country

Delivery PostCode/Zipcode

Select Your Profile

I have read and agree to the terms & conditions, including the privacy policy, return policy, and usage terms as applicable to this request.

Indications & Clinical Uses

Asfotase alfa is prescribed to address hypophosphatasia, a rare genetic disorder affecting bone development. It helps improve bone mineralization and mobility in patients with this condition. This medication is designed for long-term use under medical supervision. Commonly sought for metabolic bone disease management.

Side Effects

Patients using asfotase alfa may experience improved skeletal strength and reduced bone pain over time. Some individuals report better mobility and functional abilities as treatment progresses. Injection site reactions, such as redness or swelling, are among the most frequently observed effects.

Precautions & Warnings

Always handle asfotase alfa vials with care to avoid contamination. Do not use if the solution is discolored or contains particles. Keep unused vials refrigerated and protect from light. Dispose of needles and syringes properly after single use to prevent injury.

Avoid Interactions

Limited information exists regarding drug interactions with asfotase alfa. However, caution is advised when combining with other injectable therapies. Alcohol and certain supplements may affect overall treatment outcomes. Consult a healthcare provider before starting any new medications.

References

Frequently Asked Questions

Strensiq 40 (asfotase alfa) is used to treat hypophosphatasia, a rare genetic disorder affecting bone development and mineralization.

Store Strensiq 40 vials refrigerated between 2-8°C and protect from light. Do not freeze or shake the vials.

Common side effects include injection site reactions like redness, swelling, or itching. Some patients may experience headaches or nausea.

The safety of asfotase alfa during pregnancy has not been established. Consult a healthcare provider for personalized advice.

Yes, asfotase alfa is a prescription medication and should only be used under medical supervision.

Published by GNH India Pharmaceuticals Limited

Last updated: 17 Jun 2026

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.